Personalized drug therapy for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic gastric cancer (or cancer at the stomach–esophagus junction) that has not been treated with chemotherapy or other drugs for advanced disease.
- You have a tumor sample available for testing specific markers (HER2, CLDN18.2, PD-L1).
- You are in generally good health (able to do daily activities, with adequate organ function).
- You are not pregnant and agree to use effective birth control during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a three-drug combination (anlotinib, TQB2450, and nab-paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has progressed after prior treatment with a CLDN18.2-targeted regimen. The goal is to see if this new combination can shrink tumors and help patients live longer.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This Phase 2 trial studies whether adding two medicines (XELOX and tislelizumab) and another chemotherapy drug (PLD) around the time of surgery works better and is safe for people with stage III gastric (stomach) cancer. It is designed for tumors that are HER2-negative and PD-1/L1 positive.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This Phase 2 trial tests whether SHR-A1811—given with other medicines—works safely and effectively for people with advanced stomach or gastroesophageal junction cancer that has high HER2. It may help shrink tumors or slow cancer growth, especially if previous treatment didn’t work.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.